Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Caladrius Biosciences stock | $1.54

Own Caladrius Biosciences stock in just a few minutes.

Fact checked

Caladrius Biosciences, Inc is a biotechnology business based in the US. Caladrius Biosciences shares (CLBS) are listed on the NASDAQ and all prices are listed in US Dollars. Caladrius Biosciences employs 27 staff and has a market cap (total outstanding shares value) of USD$65.2 million.

How to buy shares in Caladrius Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Caladrius Biosciences. Find the stock by name or ticker symbol: CLBS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Caladrius Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Caladrius Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Caladrius Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Caladrius Biosciences share price

Use our graph to track the performance of CLBS stocks over time.

Caladrius Biosciences shares at a glance

Information last updated 2021-01-20.
Latest market closeUSD$1.54
52-week rangeUSD$1.05 - USD$3.21
50-day moving average USD$1.5415
200-day moving average USD$1.8245
Wall St. target priceUSD$6.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.8742

Buy Caladrius Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Caladrius Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Caladrius Biosciences price performance over time

Historical closes compared with the close of $1.54 from 2020-12-09

1 week (2021-01-15) -1.91%
1 month (2020-12-23) 1.99%
3 months (2020-10-22) -8.88%
6 months (2020-07-22) -39.13%
1 year (2020-01-22) -48.15%
2 years (2019-01-22) -67.30%
3 years (2018-01-22) 4.23
5 years (2016-01-22) 143.48%

Caladrius Biosciences financials

Gross profit TTM USD$0
Return on assets TTM -31.86%
Return on equity TTM -24.53%
Profit margin 0%
Book value $1.946
Market capitalisation USD$65.2 million

TTM: trailing 12 months

Shorting Caladrius Biosciences shares

There are currently 144,669 Caladrius Biosciences shares held short by investors – that's known as Caladrius Biosciences's "short interest". This figure is 11.3% up from 130,016 last month.

There are a few different ways that this level of interest in shorting Caladrius Biosciences shares can be evaluated.

Caladrius Biosciences's "short interest ratio" (SIR)

Caladrius Biosciences's "short interest ratio" (SIR) is the quantity of Caladrius Biosciences shares currently shorted divided by the average quantity of Caladrius Biosciences shares traded daily (recently around 258337.5). Caladrius Biosciences's SIR currently stands at 0.56. In other words for every 100,000 Caladrius Biosciences shares traded daily on the market, roughly 560 shares are currently held short.

However Caladrius Biosciences's short interest can also be evaluated against the total number of Caladrius Biosciences shares, or, against the total number of tradable Caladrius Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Caladrius Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Caladrius Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Caladrius Biosciences shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Caladrius Biosciences.

Find out more about how you can short Caladrius Biosciences stock.

Caladrius Biosciences share dividends

We're not expecting Caladrius Biosciences to pay a dividend over the next 12 months.

Have Caladrius Biosciences's shares ever split?

Caladrius Biosciences's shares were split on a 1:10 basis on 28 July 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Caladrius Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Caladrius Biosciences shares which in turn could have impacted Caladrius Biosciences's share price.

Caladrius Biosciences share price volatility

Over the last 12 months, Caladrius Biosciences's shares have ranged in value from as little as $1.05 up to $3.21. A popular way to gauge a stock's volatility is its "beta".

CLBS.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caladrius Biosciences's is 1.5536. This would suggest that Caladrius Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Caladrius Biosciences overview

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site